Canadian patent secured for PromarkerEso test for EAC
Filed with ASX · · 2 pages · English
• Patent granted in Canada protecting the intellectual property for PromarkerEso proprietary blood test for the early diagnosis of esophageal adenocarcinoma (EAC) • The patent underpins the commercialisation pathway in North America, enabling direct sales, future partnerships and licensing opportunities • Patents for the PromarkerEso diagnostic test now cover multiple jurisdictions including Austr
Proteomics International Laboratories Ltd. on 6ix
Story so far
Earlier from Proteomics International Laboratories
- Appointment of CEO and Managing Director
- Proteomics US lab CAP accredited - extends precision Dx lab
- US patent secured for PromarkerEso diagnostic test for EAC
- PromarkerD predicts risk of DKD in Aboriginal Australians
- Response to ASX Price Query
Later from Proteomics International Laboratories
- Quarterly Activities/Appendix 4C Cash Flow Report
- Appendix 4D and Interim Financial Report
- Restructure, Executive Appointment and Board Update
- Proteomics Strategic Plan
- US patent secured for PromarkerEndo
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories